

SAFETY AND EFFICACY OF ST. JOHN'S WORT (HYPERICUM) DURING PREGNANCY AND LACTATION

Jean-Jacques Dugoua^{1,2}, Edward Mills³, Daniel Perri⁴, Gideon Koren^{2,4}

¹Department of Clinical Epidemiology, Canadian College of Naturopathic Medicine, ²Motherisk Program, Hospital for Sick Children, ³Department of Clinical Epidemiology, McMaster University, ⁴Department of Clinical Pharmacology and Toxicology, University of Toronto

Corresponding Author: jeanjacques.dugoua@utoronto.ca

ABSTRACT

Background

There is a lack of basic knowledge on the part of both clinicians and patients as to the indications for use and safety of herbal medicines in pregnancy and lactation. This is one article in a series that systematically reviews the evidence for commonly used herbs during pregnancy and lactation.

Objectives

To systematically review the literature for evidence on the use, safety, and pharmacology of St. John's wort focusing on issues pertaining to pregnancy and lactation.

Methods

We searched 7 electronic databases and compiled data according to the grade of evidence found.

Results

There is very weak scientific evidence based on a case report that St John's wort is of minimal risk when taken during pregnancy. There is *in vitro* evidence from animal studies that St John's wort during pregnancy does not affect cognitive development nor cause long-term behavioral defects, but may lower offspring birth weight. There is weak scientific evidence that St. John's wort use during lactation does not affect maternal milk production nor affect infant weight, but, in a few cases, may cause colic, drowsiness or lethargy. There is weak scientific evidence that St John's wort induces CYP450 enzymes, which may lower serum medication levels below therapeutic range; this may be of concern when administering medications during pregnancy and lactation.

Conclusions

Caution is warranted with the use of St John's wort during pregnancy until further high quality human research is conducted to determine its safety. St John's wort use during lactation appears to be of minimal risk, but may cause side effects. Caution is warranted when using medications along with St John's wort.

Key Words: *St. John's wort, hypericum perforatum, pregnancy, lactation, breastfeeding, systematic review*

H*ypericum perforatum* is an aromatic perennial herb that produces a star-shaped golden yellow flower. It is native to Europe, Northern Africa, and Western Asia but can be found growing throughout the world. The common name of the plant likely originates from "Saint John's Day", June 24, around which time

the plants typically bloom. Hippocrates and Galen described the use of *Hypericum perforatum* as a treatment against demonic possession.¹

Its Latin name is derived from "hyper" meaning "over" and "eikon" meaning "apparition": a clear reference to its historical use in treating demonic possession. Its use in treating depression

dates back to the time of Swiss physician Paracelsus (ca. 1493-1541), but many authorities believe that the ancient Greeks used it for treating psychiatric disease that they labeled as demonic possession. Throughout the ages it has been used for digestive disorders, worms, wound healing, fevers, and snakebites. It was very popular until the advent of synthetic medicines.

It was "rediscovered" in the late 1970s and early 1980s by German physicians who eventually had it approved as a prescription medication for depression by Commission E in 1984. It soon outsold every other anti-depressant drug in Germany and remains covered on the national health care plan. Even today, many German physicians save synthetic antidepressants until a treatment with St. John's wort has failed. Mood disorders are among the most common health problems in women and it is diagnosed twice as often in women than men.² Almost 10% of women experience depression during pregnancy and patients with a history of depression are at risk for puerperal worsening of mood.³ A clinical dilemma often results during pregnancy and lactation due to the wish to avoid fetal and neonatal exposure to potential toxins while limiting the risks of untreated psychiatric disorders like depression. Some patients may turn to "natural" medicines such as St. John's wort that they may perceive to be a safer alternative.

However, data regarding the use of natural products in pregnancy and lactation is scarce. The Organization of Teratology Information Services (OTIS) reports in their statement on St. John's wort that "the limited data limits our ability to draw conclusions about whether there is an increased risk for birth defects or other problems associated with use of St. John's wort during pregnancy".⁴ For this reason, a systematic review of the literature regarding the efficacy and safety of the use of St. John's wort by pregnant or breastfeeding women was conducted.

METHODS

The following databases were searched from inception to June 2005: AMED, CINAHL, Cochrane CENTRAL, Cochrane Library, MedLine, Natural Database, and Natural Standard. The common name and Latin name of the herb were used as keywords along with

"pregnancy", "lactation", and "breastfeeding". In the case of a well-known active constituent of the herb, this term was also used in the search for its safety during pregnancy and lactation. In addition, the Complete German Commission E Monographs by the American Botanical Council were also searched.

Each relevant journal article was collected and referenced in a database. The nature of the findings and the grade of evidence were then abstracted and compiled in a final report. The grade of evidence for indications was evaluated as displayed in Table 1. Evidence of harm was rated as displayed in Table 2.

RESULTS

Synonyms/ Common Names/ Related Substances:⁵

Amber, amber touch-and-heal, demon chaser, *fuga daemonum*, goatweed, hardhay, hypereikon, hyperici herba, hypericum, Johns wort, klamath weed, millepertuis, Rosin rose, Saint Johns wort, Saint John's wort, Saynt Johannes wort, SJW, St Johns wort, St John's wort, tipton weed.

Indications for Use

	Grade
Mild to moderate depression ⁸⁻¹²	A
Anxiety (with valerian) ¹³	B2
Acute otitis media (with <i>Verbascum thapsus</i> , <i>Calendula flores</i> and <i>Allium sativum</i>) ¹⁴	B2
Obsessive compulsive disorder (OCD) ¹⁵	C
Psychological menopause symptoms ¹⁶	C
Premenstrual syndrome (PMS) ¹⁷	C
Chronic colitis (with <i>Taraxacum officinale</i> , <i>Melissa officinalis</i> , <i>Calendula officinalis</i> and <i>Foeniculum vulgare</i>) ¹⁸	C
Seasonal affective disorder (SAD) ¹⁹⁻²¹	C

Safety of Consumption during Pregnancy

	Level
Normal healthy baby ²²	2
Does not affect cognitive development ²³	3
No long-term behavioural deficits ²⁴	3
Lowers offspring weight ^{24,25}	3
Does not affect long-term growth and physical maturation ²⁶	3
Conflicting evidence: Non mutagenic ²⁷ / Teratogenic ²⁸	3
Increases uterine tone ²⁹	3
Emmenagogue ³⁰	4
Uterine stimulant ³⁰	4
Abortifacient ³⁰	4

A case of a 38-year-old women who started taking St. John's wort at 24 weeks gestation was reported in a letter to the editor.²² The woman's pregnancy was unremarkable, with the exception of late onset of thrombocytopenia (the author did not attribute this to St. John's wort).²² The offspring was born healthy, had a normal birth weight, normal APGAR scores, and physical examination and laboratory results were normal.²² Behavioural assessment at 4 and 23 days was within normal.²²

A study on the cognitive impact of prenatal exposure to St. John's wort in mice for 2 weeks before mating and throughout gestation found that prenatal exposure to a therapeutic dose of St. John's wort did not have a major impact on certain cognitive tasks in mice offspring.²³

A study was conducted where Sprague-Dawley rats were exposed to dietary doses of St. John's wort 1-25 times the recommended human dose.²⁵ St. John's wort had no effect on maternal weight gain or duration of gestation.²⁵ Offspring body weights were similar to controls, but some treated groups, offspring weighed significantly less than the controls.²⁵ There were no St. John's wort-related behavioural alterations on any measure.²⁵ Whole and regional brain weights of offspring at adulthood indicated no significant effects of St. John's wort.²⁵ A behavioural study on mice offspring exposed antenatally to St.

John's wort found that birth weights of male offspring were less in the St. John's wort group than in the placebo group.²⁴ Offspring in both treatment groups showed no long-term statistical differences in early developmental tasks, locomotor activity, and exploratory behaviour throughout development.²⁴ Performances on a depression task and on anxiety tasks revealed no differences between treatment groups.²⁴

St. John's wort was administered to mice in order to determine whether prenatal exposure to the herb affects long-term growth and physical maturation of mouse offspring.²⁶ Maternal administration of St. John's wort before and throughout gestation did not affect long-term growth and physical maturation of exposed mouse offspring.²⁶

A study on organogenesis found that hypericin induced teratogenic effects in whole rat embryo cultures.²⁸ A study on mammalian cells, however, showed that a standardized aqueous ethanolic extract of St. John's wort did not induce any mutagenic effects.²⁷ St. John's wort was shown to increase uterine tone in animals.²⁹

A review article on the potential value of plants as sources of anti-fertility agents reported that St. John's wort is an abortifacient, emmenagogue, and uterine stimulant.³⁰ A homeopathic preparation of *Hypericum perforatum*, called Hypericum, beyond the potency (dilution) of 12C, does not contain any molecules of the original substance. Although the principles of homeopathy are difficult to apply to evidence-based medicine research, a systematic review determined that homeopathic preparations do not significantly differ from placebo.³¹

Safety of Consumption during Lactation

	Level
Does not affect maternal milk production ³²	1b
Does not affect infant weight ³²	1b
May cause colic, drowsiness or lethargy ³²	1b
Crosses into breast milk ³³	2

A prospective observational cohort study was conducted on 33 breastfeeding women receiving St. John's wort (Group 1) and for comparison, 101 disease-matched (Group 2), and 33 age- and parity-matched non-disease controls (Group 3)³². In the group receiving St. John's wort, there were 2 cases of colic, 2 cases of drowsiness, and 1 case of lethargy.³² Specific medical treatment was not required for the infants.³²

No significant difference was observed in the frequency of maternal reports of decreased milk production among the groups, nor was a difference found in infant weight over the first year of life.³² An analysis was performed on four breast-milk samples (fore and hind milk) during an 18-hour period from a mother with post-natal depression who had taken St. John's wort during pregnancy in order to measure concentration of hypericin and hyperforin.³³ Only hyperforin was excreted into breast milk at a low level.³³ No side effects were seen in the mother or infant.³³

Part Used

Whole plant⁷.

Constituents

- Naphodianthrones⁶: hypericin, pseudohypericin
- Flavonoids⁶: quercetin, quercetrin, amentoflavone, hyperin
- Phloroglucinols⁶: hyperforin, adhyperforin
- Essential oil⁶.

Toxicity

St. John's wort may cause delayed hypersensitivity photodermatitis.³⁴⁻³⁶ Hypericin is believed to be the photosensitizing agent present in St. John's wort.^{37,38}

Pharmacology

St. John's wort effects on serotonin may be primarily responsible for its antidepressant activity.³⁹ Extracts of St. John's wort inhibit the reuptake of serotonin, norepinephrine, and dopamine *in vitro*.³⁹⁻⁴¹ Hyperforin and adhyperforin were shown to modulate the effects of serotonin, dopamine, and noradrenaline, and to act as serotonergic 5-HT₃ and 5-HT₄ receptor antagonists.⁴¹⁻⁴⁴ Hypericin inhibits *in vitro* almost irreversibly both type A and B monoamine oxidase (MAO) in rat brain mitochondria.⁴⁵ In human and animal cancer cells, hyperforin

inhibited tumour cell growth by induction of apoptosis.⁴⁶ Topical application of St. John's wort inhibits the proliferation of T lymphocytes in inflammatory skin disorders.⁴⁷ St. John's wort induces some of the cytochrome P450 (CYP) enzymes and may interfere with drug metabolism.⁴⁸ St. John's wort has antibacterial activity.⁴⁹

Drug Interactions

St. John's wort has displayed consistent pharmacokinetic drug interactions in clinical trials resulting in reduced systemic exposure to many conventional drugs.

The following drugs should be noted for potential interactions:

5-HT ₁ agonists ^{50, 51}
Alprozolam ⁵²
Aminolaevulinic acid ⁵³
Amitriptyline ⁵⁴⁻⁵⁶
Analgesics with serotonergic activity ^{39-41, 51}
Antidepressants ^{51, 57-59}
Barbituates ⁶⁰
Carbamazepine ⁶¹
Cyclosporine ^{50, 55, 56, 62-72}
Digoxin ^{50, 56, 73-75}
Dextromethorphan ^{39-41, 51}
Fenfluramine ⁵⁹
Fexofenadine ⁷⁶
Irinotecan ^{77, 78}
Monoamine Oxidase Inhibitors (MAOIs) ^{41, 43}
Mycophenolate mofetil ⁷⁹
Narcotics ^{60, 80}
Nelazodone ⁸¹
Nonnucleoside Reverse Transcriptase Inhibitors ^{55, 82, 83}
Nortriptyline ^{54, 56}
Oral contraceptives ^{50, 84-86}
Paroxetine ^{51, 58, 59}
Phenobarbital ⁵⁰
Phenprocoumon ⁵⁰
Phenytoin ⁵⁰
Photosensitizing drugs ⁵⁷
Protease Inhibitors (PIs) ^{50, 56, 82}
Reserpine ⁶⁰
Sertraline ⁸¹
Simvastatin ⁸⁷
Tacrolimus ^{79, 88}
Theophylline ^{50, 56, 89}
Warfarin ^{50, 84, 90}
Drugs metabolized by cytochrome P450 enzymes ^{48, 50, 52, 56, 65, 74, 75, 82, 84, 91}

DISCUSSION

There is good evidence to support the use of St. John's wort for mild to moderate cases of depression. There is low-level evidence supporting the use of St. John's wort, alone or in combination with other medicinal herbs, for the following conditions: anxiety, acute otitis media, obsessive compulsive disorder (OCD), psychological menopause symptoms, premenstrual syndrome (PMS), chronic colitis, and seasonal affective disorder (SAD). With weak evidence as to the safety of consumption of St. John's wort during pregnancy, caution is warranted. One case was reported of the birth of a normal healthy baby following St. John's wort consumption during pregnancy. A small number of animal studies showed that St. John's wort:

1. does not affect cognitive development,
2. causes no long-term behavioural deficits, and
3. does not affect long-term growth and physical maturation.

However, other animal studies report lower birth weight in offspring's when St. John's wort is consumed during pregnancy and that it may increase uterine tone. There is also conflicting

evidence as to the teratogenicity of hypericin, yet non-mutagenic activity of the whole plant.

During lactation, St. John's wort should be used with caution due to potential side effects of colic, drowsiness, and lethargy. Despite good scientific evidence that St. John's wort consumption during lactation does not affect maternal milk production nor affect infant weight, a few cases of colic, drowsiness, or lethargy were reported with its use. There is also evidence that St. John's wort constituents cross into breast milk.

While traditional and common use has not indicated any substantive risks of taking this herb during pregnancy and lactation, clearly more rigorous and well-controlled research is needed in this area. Clinicians and patients should also be concerned about the potential for interactions that may occur between St. John's wort and numerous prescription medications. This issue has greater significance when the possibility for increased exposure or toxicity to the developing fetus might result from altered drug metabolism due to interaction. Patients should also be vigilant about sun exposure as St. John's wort may cause photodermatitis.

TABLE 1 Grades for evidence for efficacy

GRADE	EVIDENCE
A	VERY STRONG SCIENTIFIC EVIDENCE Statistically significant evidence of benefit from one or more systematic reviews/ meta-analysis.
B1	STRONG SCIENTIFIC EVIDENCE Statistically significant evidence of benefit from one or more properly conducted random control trials (RCTs).
B2	GOOD SCIENTIFIC EVIDENCE Statistically significant evidence of benefit from one or more RCTs. The RCTs, however, are either of small sample size OR have discrepancies in their methodologies.
C	FAIR SCIENTIFIC EVIDENCE Statistically significant evidence of benefit from one or more cohort studies OR outcome studies.
D	WEAK SCIENTIFIC EVIDENCE Evidence from case series.
E	INDIRECT AND/OR CLINICAL EVIDENCE Evidence from case reports OR expert opinion OR laboratory studies.
F	HISTORICAL OR TRADITIONAL EVIDENCE Historical or traditional use by medical professionals, herbalists, scientists, or aboriginal groups.

TABLE 2 Levels for evidence for harm

LEVEL	EVIDENCE
1a	STRONG SCIENTIFIC EVIDENCE Statistically significant evidence from one or more systematic reviews or RCTs.
1b	GOOD SCIENTIFIC EVIDENCE Statistically significant evidence from one or more cohort studies OR control study.
1c	WEAK SCIENTIFIC EVIDENCE Evidence from one or more case series.
2	VERY WEAK SCIENTIFIC EVIDENCE Evidence based on case reports.
3	IN VITRO SCIENTIFIC EVIDENCE Evidence based on scientific studies conducted on animals, insects or microorganisms OR laboratory studies on human cells.
4	INDIRECT EVIDENCE Evidence based on scientific theory OR expert opinion.
5	UNKNOWN No available information.

REFERENCES

1. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. *BMJ* 2000; 321:536-9.
2. Weissman MM, Olfson M. Depression in women: implications for health care research. *Science* 1995; 269:799-801.
3. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. *Am J Psychiatry* 1996; 153:592-606.
4. OTIS. Organization of Teratology Information Services: (www.OTISpregnancy.org). 2004.
5. Jellin JM, Batz F, Hitchens K. Natural medicines comprehensive database 3rd Edition. Stockton, CA: Therapeutic Research Faculty, 2002:1530.
6. Upton R. St Johns Wort - Hypericum perforatum. American Herbal Pharmacopoeia - American Botanical Council 1996.
7. Brinker F. The toxicology of botanical medicines. Sandy, Oregon: Eclectic Medical Publications, 2000:296.
8. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. *BMJ* 1996; 313:253-8.
9. Linde K, Mulrow CD. St John's wort for depression. *Cochrane Database Syst Rev* 2000:CD000448.
10. Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. 1999.
11. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. *Int Clin Psychopharmacol* 2001; 16:239-52.
12. Gaster B, Holroyd J. St John's wort for depression: a systematic review. *Arch Intern Med.* 2000; 160:152-6.
13. Panijel M. [Treatment of moderately severe anxiety states]. *Therapiewoche* 1985; 35:4659-68.
14. Sarrell EM, Mandelberg A, Cohen HA. Efficacy of naturopathic extracts in the management of ear pain associated with acute otitis media. *Archives of Pediatrics & Adolescent Medicine* 2001; 155:796-9.
15. Taylor LH, Kobak KA. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. *J Clin Psychiatry* 2000; 61:575-8.
16. Grube B, Walper A, Wheatley D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin. *Adv Ther* 1999; 16:177-86.
17. Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. *BJOG* 2000; 107:870-6.
18. Chakurski I, Matev M, Koichev A, Angelova I, Stefanov G. [Treatment of chronic colitis with an herbal combination of Taraxacum officinale, Hipericum perforatum, Melissa officinaliss,

- Calendula officinalis* and *Foeniculum vulgare*]. *Vutr Boles* 1981; 10:51-4.
19. Martinez B, Kasper S, Ruhrmann S, Moller HJ. *Hypericum* in the treatment of seasonal affective disorders. *J Geriatr Psychiatry Neurol* 1994; 7:S29-33.
 20. Kasper S. Treatment of seasonal affective disorder (SAD) with *hypericum* extract. *Pharmacopsychiatry* 1997; 30:89-93.
 21. Wheatley D. *Hypericum* in seasonal affective disorder (SAD). *Curr Med Res Opin* 1999; 15:33-7.
 22. Grush LR, Nierenberg A, Keefe B, Cohen LS. St John's wort during pregnancy. *JAMA* 1998; 280:1566.
 23. Rayburn WF, Gonzalez CL, Christensen HD, Harkins TL, Kupiec TC. Impact of *hypericum* (St.-John's-wort) given prenatally on cognition of mice offspring. *Neurotoxicol Teratol* 2001; 23:629-37.
 24. Rayburn WF, Christensen HD, Gonzalez CL. Effect of antenatal exposure to Saint John's wort (*Hypericum*) on neurobehavior of developing mice. *Am J Obstet Gynecol* 2000; 183:1225-31.
 25. Cada AM, Hansen DK, LaBorde JB, Ferguson SA. Minimal effects from developmental exposure to St. John's wort (*Hypericum perforatum*) in Sprague-Dawley rats. *Nutr Neurosci* 2001; 4:135-41.
 26. Rayburn WF, Gonzalez CL, Christensen HD, Stewart JD. Effect of prenatally administered *hypericum* (St John's wort) on growth and physical maturation of mouse offspring. *Am J Obstet Gynecol* 2001; 184:191-5.
 27. Okpanyi SN, Lidzba H, Scholl BC, Miltenburger HG. [Genotoxicity of a standardized *Hypericum* extract]. *Arzneimittelforschung*. 1990; 40:851-5.
 28. Chan LY, Chiu PY, Lau TK. A study of *hypericin*-induced teratogenicity during organogenesis using a whole rat embryo culture model. *Fertil Steril* 2001; 76:1073-4.
 29. Shipochliev T. [Uterotonic action of extracts from a group of medicinal plants]. *Vet Med Nauki*. 1981; 18:94-8.
 30. Farnsworth NR, Bingel AS, Cordell GA, Crane FA, Fong HH. Potential value of plants as sources of new antifertility agents I. *J Pharm Sci* 1975; 64:535-98.
 31. Ernst E. A systematic review of systematic reviews of homeopathy. *Br J Clin Pharmacol* 2002; 54:577-82.
 32. Lee A, Minhas R, Matsuda N, Lam M, Ito S. The safety of St. John's wort (*Hypericum perforatum*) during breastfeeding. *J Clin Psychiatry* 2003; 64:966-8.
 33. Klier CM, Schafer MR, Schmid-Siegel B, Lenz G, Mannel M. St. John's wort (*Hypericum perforatum*)--is it safe during breastfeeding? *Pharmacopsychiatry* 2002; 35:29-30.
 34. Duke JA. Handbook of medicinal herbs. Boca Raton: CRC, 1985.
 35. Benner MH, Lee HJ. Toxic reactions to plant products sold in health food stores. *Med Lett* 1979; 21:29-32.
 36. Mitchell J, Rook A. Botanical dermatology - plants and plant products injurious to the skin. Vancouver: Greengrass, 1979.
 37. Frohne D, Pfander HJ. A colour atlas of poisonous plants. London: Wolfe, 1984.
 38. Newall CA, Anderson LA, Phillipson JD. Herbal medicines : a guide for health-care professionals. London, UK: Pharmaceutical Press, 1996:296.
 39. Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of *hypericum perforatum*. *Pharmacopsychiatry* 2001; 34:45-9.
 40. Kleber E, Obry T, Hippeli S, et al. Biochemical activities of extracts from *Hypericum perforatum*. *Arzneimittelforschung* 1999; 49:106-9.
 41. Muller WE, Singer A, Wonnemann M, Hafner U, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of *hypericum* extract. *Pharmacopsychiatry* 1998; 31:16-21.
 42. Chatterjee SS, Noldner M, Koch E, Erdelmeier C. Antidepressant activity of *hypericum perforatum* and hyperforin: the neglected possibility. *Pharmacopsychiatry* 1998; 31:7-15.
 43. Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na⁺. *J Pharmacol Exp Ther* 1999; 290:1363-8.
 44. Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of *Hypericum perforatum* L. in biochemical models of antidepressant activity. *Life Sci* 2001; 68:1593-605.
 45. Suzuki O, et al. Inhibition of monoamine oxidase by *hypericin*. *Planta Med* 1984; 50:272-4.
 46. Schempp CM, Kirkin V, Simon-Haarhaus B, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. *Oncogene* 2002; 21:1242-50.
 47. Schempp CM, Winghofer B, Ludtke R, Simon-Haarhaus B, Schopf E, Simon JC. Topical application of St John's wort (*Hypericum perforatum* L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. *Br J Dermatol* 2000; 142:979-84.
 48. Wang Z, Gorski JC, Hamman MA, et al. The effects of St. John's wort (*Hypericum perforatum*)

- on human cytochrome P450 activity. *Clin Pharmacol Ther* 2001; 70:317-26.
49. Schempp CM, Pelz K, Wittmer A, Schopf E, Simon JC. Antibacterial activity of hyperforin from St John's wort, against multiresistant *Staphylococcus aureus* and gram-positive bacteria. *Lancet* 1999; 353:2129.
 50. Henderson L, Yue QY, Bergquist C, et al. St John's wort (*Hypericum perforatum*): drug interactions and clinical outcomes. *Br J Clin Pharmacol* 2002; 54:349-56.
 51. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. *Neurology* 2002; 58:130-3.
 52. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. *JAMA* 2003; 290:1500-4.
 53. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* 2001; 144.
 54. Roots I, Johne A, Schmider B, Brockmoller J, et al. Interaction of a herbal extract from St. John's wort with amitriptyline and its metabolites. *Clin Pharmacol Ther* 2000; 67:159.
 55. Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. *Clin Pharmacol Ther* 2000; 68:598-604.
 56. Schulz V. Incidence and clinical relevance of the interactions and side effects of *Hypericum* preparations. *Phytomedicine* 2001; 8:152-60.
 57. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med* 1998; 158:2200-11.
 58. Gordon JB. SSRIs and St. John's Wort: possible toxicity? *Am Fam Physician* 1998; 57:950-3.
 59. Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: A survey of effectiveness, safety, and tolerability. *Pharmacotherapy* 2000; 20:568-74.
 60. Upton R. St. John's wort, *Hypericum perforatum*: Quality control, analytical and therapeutic monograph. American Herbal Pharmacopoeia. Santa Cruz, CA, 1997:1-32.
 61. Burstein AH, Horton RL, Dunn T, et al. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. *Clin Pharmacol Ther* 2000; 68:605-12.
 62. Abul-Ezz SR, Barone GW, Gurley BJ, et al. Effect of herbal supplements on cyclosporine blood levels and associated acute rejection, Am Soc of Nephrol Ann Mtg, Toronto, CAN, 2000.
 63. Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (*Hypericum perforatum*) with the immunosuppressant cyclosporin. *Int J Clin Pharmacol Ther* 2000; 38:500-2.
 64. Gurley BJ, Barone GW. Herb-drug interaction involving St. John's wort and cyclosporine, AAPS Ann Mtg & Expo, Indianapolis, IN, Oct29- Nov2, 2000. Vol. presentation #3443.
 65. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. *Lancet* 2000; 355:548-9.
 66. Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John's wort and cyclosporin. *Ann Pharmacother* 2000; 34:1013-6.
 67. Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St John's wort with ciclosporin. *Lancet* 2000; 355:1912.
 68. Moschella C, Jaber BL. Interaction between cyclosporine and *Hypericum perforatum* (St. John's wort) after organ transplantation. *Amer J Kidney Dis* 2001; 38:1105-7.
 69. Karliova M, Treichel U, Malago M, et al. Interaction of *Hypericum perforatum* (SJW) with cyclosporin A metabolism in a patient after liver transplantation. *J Hepatol* 2000; 33:853-5.
 70. Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M. Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient. *Nephrol Dial Transplant* 2000; 15:1473-4.
 71. Ernst E. St. John's Wort supplements endanger the success of organ transplantation. *Arch Surg* 2002; 137:316-9.
 72. Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. *Br J Clin Pharmacol* 2003; 55:203-11.
 73. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 1999; 66:338-45.
 74. Cheng TO. St. John's wort interaction with digoxin [letter]. *Arch Intern Med* 2000; 160:2548.
 75. Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. *Br J Clin Pharmacol* 2002; 53:75-82.
 76. Wang Z, Hamman MA, Huang SM, et al. Effect of St. John's wort on the pharmacokinetics of fexofenadine. *Clin Pharmacol Ther* 2002; 71:414-20.
 77. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. *J Natl Cancer Inst* 2002; 94:1247-9.

78. Mathijssen RHJ, Verweij J, De Bruijn P, et al. Modulation of irinotecan (CPT-11) metabolism by St. John's wort in cancer patients, American Association for Cancer Research Annual Meeting, San Francisco, April, 2002.
79. Mai I, Stormer E, Bauer S, et al. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. *Nephrol Dial Transplant* 2003; 18:819-22.
80. Hussain MD, Teixeira MG. Saint John's wort and analgesia: effect of Saint John's wort on morphine induced analgesia, AAPS Ann Mtg & Expo, Indianapolis, IN, Oct 29- Nov 2, 2000. Vol. presentation #3453.
81. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. *J Geriatr Psychiatry Neurol* 1999; 12:7-10.
82. Piscitelli SC, Burstein AH, Chait D, et al. Indinavir concentrations and St. John's wort. *Lancet* 2000; 355:547-8.
83. de Maat M, Hoetelmans R, Mathot R, et al. Drug interaction between St. John's wort and nevirapine. *AIDS* 2001; 15:420-1.
84. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (*Hypericum perforatum*). *Lancet* 2000; 355:576-7.
85. Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. *Br J Clin Pharmacol* 2003; 55:112-3.
86. Gorski JC, Hamman MA, Wang Z, et al. The effect of St. John's wort on the efficacy of oral contraceptives. *Clin Pharmacol Ther* 2001; 71:P25.
87. Sugimoto K, Ohmori M, Tsuruoka S. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. *Clin Pharmacol Ther* 2001; 70:518-24.
88. Mai I, Bauer S, Krueger H, et al. Wechselwirkungen von Johanniskraut mit tacrolimus bei nierentransplantierten Patienten, Symposium Phytopharmaka VII, Berlin, GER, October, 2001. *Forschung und Klinische Anwendung*.
89. Nebel A, Schneider BJ, Baker RA, et al. Potential metabolic interaction between St. John's wort and theophylline. *Ann Pharmacother* 1999; 33:502.
90. Groning R, Breikreutz J, Muller RS. Physico-chemical interactions between extracts of *Hypericum perforatum* L. and drugs. *Eur J Pharm Biopharm* 2003; 56:231-6.
91. Roby CA, Anderson GD, Kantor E, et al. St. John's wort: Effect on CYP3A4 activity. *Clin Pharmacol Ther* 2000; 67:451-7.